Folate, Vitamin B12 Tied to GDM Risk in Early Pregnancy
|
By LabMedica International staff writers Posted on 12 Oct 2021 |

Image: The SCIEX QTRAP 6500+ system combines triple quadrupole mass spectrometry with linear ion trap (LIT) (Photo courtesy of Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences)
Gestational diabetes mellitus (GDM) is a common medical disorder in pregnancy, estimated to affect more than 20 million pregnancies worldwide, and causes significant short- and long-term consequences to both the women and their offspring.
Folate and B12 are essential micronutrients for the metabolism of single carbon atoms (known as 1-C metabolism) and these pathways are involved in DNA methylation and synthesis of amino acids, nucleic acids and lipids. Low vitamin B12 and low/high folate levels may contribute to GDM risk, but there is conflicting evidence.
Health Scientist at the Warwick Medical School (Coventry, UK) carried out a prospective, multi-center, multi-ethnic cohort study of 4,746 participants who were pregnant women aged between 18 and 45 years who were at less than 16 weeks of gestation. A random blood sample at booking and fasting and two hour blood samples at Oral Glucose Tolerance Test (OGTT) using 75 grams of anhydrous glucose after an overnight fast of at least 10 hours were taken.
Plasma glucose was determined by the hexokinase enzymatic method using a Synchron CX7 auto-analyzer (Beckman Coulter, Fullerton, CA, USA). Serum B12 and folate were measured by electro-chemiluminescent immunoassay (Roche Cobas analyzer, Roche Diagnostics, Burgess Hill, UK). Plasma total homocysteine (tHcy) was determined by stable isotopic dilution analysis using a Shimadzu HPLC system (Milton Keynes, UK) with an auto-sampler coupled to the detection system of an AB Sciex 6500 QTrap tandem mass spectrometer (liquid chromatography mass spectrometry [LCMS]) (Applied Biosystems, Warrington, UK).
The investigators reported that GDM prevalence was between 12.5% and 14.7%. Folate deficiency (1.3%) was rare but B12 insufficiency (42.3% at <220 pmol/L) and folate excess (36.5%) were common in early pregnancy. Early pregnancy median B12 levels were lower and folate levels higher, in women who were diagnosed with GDM at 26–28 weeks and B12 was negatively associated with fasting plasma glucose. Total homocysteine was inversely associated with blood glucose level and risk of GDM. The associations strengthened when adjusted for BMI, suggesting that the total homocysteine effect on blood glucose level/GDM is independent of BMI, B12 and folate.
The authors concluded that B12 insufficiency and folate excess were common in early pregnancy. Low B12 and high folate levels in early pregnancy were associated with small but statistically significant changes in maternal blood glucose level and higher relative risk (RR) of GDM. The findings warrant additional studies on the role of unmetabolized folic acid in glucose metabolism and investigating the effect of optimizing early pregnancy or pre-conception B12 and folate levels on subsequent hyperglycemia. The study was originally published on July 22, 2021 in the journal Diabetologia.
Related Links:
Warwick Medical School
Beckman Coulter
Roche Diagnostics
Shimadzu
Applied Biosystems
Folate and B12 are essential micronutrients for the metabolism of single carbon atoms (known as 1-C metabolism) and these pathways are involved in DNA methylation and synthesis of amino acids, nucleic acids and lipids. Low vitamin B12 and low/high folate levels may contribute to GDM risk, but there is conflicting evidence.
Health Scientist at the Warwick Medical School (Coventry, UK) carried out a prospective, multi-center, multi-ethnic cohort study of 4,746 participants who were pregnant women aged between 18 and 45 years who were at less than 16 weeks of gestation. A random blood sample at booking and fasting and two hour blood samples at Oral Glucose Tolerance Test (OGTT) using 75 grams of anhydrous glucose after an overnight fast of at least 10 hours were taken.
Plasma glucose was determined by the hexokinase enzymatic method using a Synchron CX7 auto-analyzer (Beckman Coulter, Fullerton, CA, USA). Serum B12 and folate were measured by electro-chemiluminescent immunoassay (Roche Cobas analyzer, Roche Diagnostics, Burgess Hill, UK). Plasma total homocysteine (tHcy) was determined by stable isotopic dilution analysis using a Shimadzu HPLC system (Milton Keynes, UK) with an auto-sampler coupled to the detection system of an AB Sciex 6500 QTrap tandem mass spectrometer (liquid chromatography mass spectrometry [LCMS]) (Applied Biosystems, Warrington, UK).
The investigators reported that GDM prevalence was between 12.5% and 14.7%. Folate deficiency (1.3%) was rare but B12 insufficiency (42.3% at <220 pmol/L) and folate excess (36.5%) were common in early pregnancy. Early pregnancy median B12 levels were lower and folate levels higher, in women who were diagnosed with GDM at 26–28 weeks and B12 was negatively associated with fasting plasma glucose. Total homocysteine was inversely associated with blood glucose level and risk of GDM. The associations strengthened when adjusted for BMI, suggesting that the total homocysteine effect on blood glucose level/GDM is independent of BMI, B12 and folate.
The authors concluded that B12 insufficiency and folate excess were common in early pregnancy. Low B12 and high folate levels in early pregnancy were associated with small but statistically significant changes in maternal blood glucose level and higher relative risk (RR) of GDM. The findings warrant additional studies on the role of unmetabolized folic acid in glucose metabolism and investigating the effect of optimizing early pregnancy or pre-conception B12 and folate levels on subsequent hyperglycemia. The study was originally published on July 22, 2021 in the journal Diabetologia.
Related Links:
Warwick Medical School
Beckman Coulter
Roche Diagnostics
Shimadzu
Applied Biosystems
Latest Clinical Chem. News
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
Channels
Molecular Diagnostics
view channel
Blood-Based Epigenetic Signals Enable Osteosarcoma Disease Monitoring
Osteosarcoma is a rare but aggressive pediatric bone cancer where recurrence and metastasis remain difficult to detect early. Imaging-based surveillance can miss small lesions and exposes children to repeated... Read more
Host–Virus Genetic Interactions Drive Nasopharyngeal Cancer Risk
Epstein–Barr virus (EBV) infects more than 95% of adults worldwide, yet only a small fraction develops EBV‑associated cancers such as nasopharyngeal carcinoma. Explaining this divergence requires understanding... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read moreMicrobiology
view channel
Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read morePathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more







